Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Quell Therapeutics
Biotech
Quell halts transplant trial to focus on 'chill not kill' Treg
Quell is pressing pause on an engineered regulatory T-cell therapy for liver transplant patients to focus on a preclinical autoimmune candidate.
James Waldron
Feb 5, 2026 6:00am
AstraZeneca pays $85M to Quell diabetes with 'one and done' drug
Jun 9, 2023 2:00am
New CEO will lead Teva at top of new year—Chutes & Ladders
Dec 2, 2022 9:30am
Next-gen CAR player Quell Therapeutics drives into the fast lane
Nov 29, 2021 7:15am
